CANCER CARE: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer (Version 2.2) (2024)

Other · Paul E. Marik, MD · 2024

Paul E. Marik et al., 2024: Marik's full Cancer Care monograph lists ivermectin in its 'Tier One' drugs at 12-18 mg daily, and its dosing section says 'a daily dose of 12-18 mg may be effective (prescribed indefinitely)'.

Ivermectin 12-18 mg daily (? 1mg/kg/day)

68 (PDF p.68)

Paul E. Marik et al., 2024: Marik's full Cancer Care monograph lists ivermectin in its 'Tier One' drugs at 12-18 mg daily, and its dosing section says 'a daily dose of 12-18 mg may be effective (prescribed indefinitely)'. C8 dosing origin – this is the '12-18 mg daily' figure, and the nearest published source to the book's '12 mg daily' testimonial dose. Record fields: Tier One list item 6 reads 'Ivermectin 12-18 mg daily (? 1mg/kg/day)' (the question mark is Marik's own uncertainty marking). Dosing section (p.93): 'The optimal dosing strategy with ivermectin is unclear. De Castro et al reported the use of 1mg/kg/day for up to 6 months in three pediatric patients with refractory AML without untoward side effects. Ishiguro et al reported the use of ivermectin 12 mg twice weekly. Anecdotal evidence suggest that a daily dose of 12-18 mg may be effective (prescribed indefinitely).' Also states 'As ivermectin does not cross the blood-brain barrier, it is likely ineffective for brain tumors' – directly relevant to C9. Error to note: the monograph says 'Ivermectin was approved by the FDA for use in humans in 1978' (p.92), a third wrong date alongside the book's 1987. This is a self-published clinical guide, not a trial; Marik declares no formal conflicts in the document.